Literature DB >> 33363005

Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung.

Philipp Hoegen1,2,3,4, Clemens Lang2,5, Sati Akbaba1,2,3,6, Peter Häring2,5, Mona Splinter2,5, Annette Miltner4, Marion Bachmann4, Christiane Stahl-Arnsberger4, Thomas Brechter4, Rami A El Shafie1,2,3, Fabian Weykamp1,2,3, Laila König1,2,3, Jürgen Debus1,2,3,4,7,8, Juliane Hörner-Rieber1,2,3,4.   

Abstract

PURPOSE: To evaluate the potential of cone-beam-CT (CB-CT) guided adaptive radiotherapy (ART) for locally advanced non-small cell lung cancer (NSCLC) for sparing of surrounding organs-at-risk (OAR).
MATERIALS AND METHODS: In 10 patients with locally advanced NSCLC, daily CB-CT imaging was acquired during radio- (n = 4) or radiochemotherapy (n = 6) for simulation of ART. Patients were treated with conventionally fractionated intensity-modulated radiotherapy (IMRT) with total doses of 60-66 Gy (pPlan) (311 fraction CB-CTs). OAR were segmented on every daily CB-CT and the tumor volumes were modified weekly depending on tumor changes. Doses actually delivered were recalculated on daily images (dPlan), and voxel-wise dose accumulation was performed using a deformable registration algorithm. For simulation of ART, treatment plans were adapted using the new contours and re-optimized weekly (aPlan).
RESULTS: CB-CT showed continuous tumor regression of 1.1 ± 0.4% per day, leading to a residual gross tumor volume (GTV) of 65.3 ± 13.4% after 6 weeks of radiotherapy (p = 0.005). Corresponding PTVs decreased to 83.7 ± 7.8% (p = 0.005). In the actually delivered plans (dPlan), both conformity (p = 0.005) and homogeneity (p = 0.059) indices were impaired compared to the initial plans (pPlan). This resulted in higher actual lung doses than planned: V20Gy was 34.6 ± 6.8% instead of 32.8 ± 4.9% (p = 0.066), mean lung dose was 19.0 ± 3.1 Gy instead of 17.9 ± 2.5 Gy (p = 0.013). The generalized equivalent uniform dose (gEUD) of the lung was 18.9 ± 3.1 Gy instead of 17.8 ± 2.5 Gy (p = 0.013), leading to an increased lung normal tissue complication probability (NTCP) of 15.2 ± 13.9% instead of 9.6 ± 7.3% (p = 0.017). Weekly plan adaptation enabled decreased lung V20Gy of 31.6 ± 6.2% (-3.0%, p = 0.007), decreased mean lung dose of 17.7 ± 2.9 Gy (-1.3 Gy, p = 0.005), and decreased lung gEUD of 17.6 ± 2.9 Gy (-1.3 Gy, p = 0.005). Thus, resulting lung NTCP was reduced to 10.0 ± 9.5% (-5.2%, p = 0.005). Target volume coverage represented by conformity and homogeneity indices could be improved by weekly plan adaptation (CI: p = 0.007, HI: p = 0.114) and reached levels of the initial plan (CI: p = 0.721, HI: p = 0.333).
CONCLUSION: IGRT with CB-CT detects continuous GTV and PTV changes. CB-CT-guided ART for locally advanced NSCLC is feasible and enables superior sparing of healthy lung at high levels of plan conformity.
Copyright © 2020 Hoegen, Lang, Akbaba, Häring, Splinter, Miltner, Bachmann, Stahl-Arnsberger, Brechter, El Shafie, Weykamp, König, Debus and Hörner-Rieber.

Entities:  

Keywords:  adaptive radiotherapy; cone-beam computed tomography; lung cancer; non-small cell lung cancer; normal tissue; organs at risk; pneumonitis; quality assessment

Year:  2020        PMID: 33363005      PMCID: PMC7756078          DOI: 10.3389/fonc.2020.564857

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  70 in total

1.  An assessment of cone beam CT in the adaptive radiotherapy planning process for non-small-cell lung cancer patients.

Authors:  Aileen Duffton; Stephen Harrow; Carolynn Lamb; Mark McJury
Journal:  Br J Radiol       Date:  2016-04-07       Impact factor: 3.039

2.  The ANACONDA algorithm for deformable image registration in radiotherapy.

Authors:  Ola Weistrand; Stina Svensson
Journal:  Med Phys       Date:  2015-01       Impact factor: 4.071

3.  Time and dose-related changes in lung perfusion after definitive radiotherapy for NSCLC.

Authors:  Katherina P Farr; Azza A Khalil; Ditte S Møller; Henrik Bluhme; Stine Kramer; Anni Morsing; Cai Grau
Journal:  Radiother Oncol       Date:  2017-12-01       Impact factor: 6.280

4.  Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer.

Authors:  Matthias Guckenberger; Juergen Wilbert; Anne Richter; Kurt Baier; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-12       Impact factor: 7.038

5.  Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.

Authors:  Geert Bosmans; Angela van Baardwijk; André Dekker; Michel Ollers; Stofferinus Wanders; Liesbeth Boersma; Philippe Lambin; Dirk De Ruysscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

6.  Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer.

Authors:  Rebecca Smith-Bindman; Jafi Lipson; Ralph Marcus; Kwang-Pyo Kim; Mahadevappa Mahesh; Robert Gould; Amy Berrington de González; Diana L Miglioretti
Journal:  Arch Intern Med       Date:  2009-12-14

7.  Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of arteriovenous malformations and acoustic neuromas.

Authors:  Thierry Gevaert; Marc Levivier; Thomas Lacornerie; Dirk Verellen; Benedikt Engels; Nick Reynaert; Koen Tournel; Michael Duchateau; Truus Reynders; Tom Depuydt; Christine Collen; Eric Lartigau; Mark De Ridder
Journal:  Radiother Oncol       Date:  2012-08-10       Impact factor: 6.280

8.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Authors:  Mary Feng; Feng-Ming Kong; Milton Gross; Shaneli Fernando; James A Hayman; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

9.  Treating locally advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy.

Authors:  Hannah E Bainbridge; Martin J Menten; Martin F Fast; Simeon Nill; Uwe Oelfke; Fiona McDonald
Journal:  Radiother Oncol       Date:  2017-10-04       Impact factor: 6.280

10.  Fatal Radiation Pneumonitis: Literature Review and Case Series.

Authors:  Stephen Keffer; Christopher L Guy; Elisabeth Weiss
Journal:  Adv Radiat Oncol       Date:  2019-08-31
View more
  3 in total

Review 1.  Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.

Authors:  William A Hall; Eric Paulson; X Allen Li; Beth Erickson; Christopher Schultz; Alison Tree; Musaddiq Awan; Daniel A Low; Brigid A McDonald; Travis Salzillo; Carri K Glide-Hurst; Amar U Kishan; Clifton D Fuller
Journal:  CA Cancer J Clin       Date:  2021-11-18       Impact factor: 508.702

2.  PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.

Authors:  Matthias Mäurer; Lukas Käsmann; Daniel F Fleischmann; Michael Oertel; Danny Jazmati; Daniel Medenwald
Journal:  Radiat Oncol       Date:  2022-02-09       Impact factor: 3.481

Review 3.  Deep learning methods for enhancing cone-beam CT image quality toward adaptive radiation therapy: A systematic review.

Authors:  Branimir Rusanov; Ghulam Mubashar Hassan; Mark Reynolds; Mahsheed Sabet; Jake Kendrick; Pejman Rowshanfarzad; Martin Ebert
Journal:  Med Phys       Date:  2022-07-18       Impact factor: 4.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.